Clinical Trials on Melanosis in United States

Total 1809 results

San Diego Pacific Oncology & Hematology Associates

Unknown

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Suspended

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
Astex Pharmaceuticals, Inc.

Completed

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Baylor Health Care System
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
St. Luke's Medical Center

Completed

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Melanoma (Skin)

United States
University of Colorado, Denver
National Cancer Institute (NCI)

Completed

Gene Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
M.D. Anderson Cancer Center
Cortice Biosciences, Inc.

Withdrawn

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Kelly McMasters

Recruiting

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Melanoma (Skin)

United States
Louisiana State University Health Sciences Center...

Terminated

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); American Society of Clinical Oncology; Society...

Completed

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Melanoma (Skin)

United States
University of Miami

Completed

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
St. Luke's Medical Center

Unknown

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Baylor Health Care System
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Melanoma (Skin)

United States
Bristol-Myers Squibb

Completed

Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

A Phase I/II Study of Dasatinib and Dacarbazine

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Iovance Biotherapeutics, Inc.

Active, not recruiting

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.; Exelixis

Active, not recruiting

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma | Skin Cancer

United States
National Cancer Institute (NCI)

Terminated

Lapatinib in Stage IV Melanoma With ERBB4 Mutations

Malignant Melanoma

United States
M.D. Anderson Cancer Center
American Regent, Inc.

Terminated

Study of Weekly LOC-paclitaxel Injection for Melanoma

Melanoma

United States
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
Cadila Pharnmaceuticals

Terminated

Safety Study of CADI-05 in Patients With Advanced Stage Melanoma

Stage III or Stage IV Melanoma

United States
Mt. Sinai Medical Center, Miami
Bayer; Chiron Corporation

Completed

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Malignant Melanoma

United States

Clinical Trials on Melanosis in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations